中国小儿血液与肿瘤杂志
中國小兒血液與腫瘤雜誌
중국소인혈액여종류잡지
JOURNAL OF CHINA PEDIATRIC BLOOD AND CANCER
2014年
6期
320-323
,共4页
刘娜%张宝玺%赵晓庆%马夫天%吴晓莉
劉娜%張寶璽%趙曉慶%馬伕天%吳曉莉
류나%장보새%조효경%마부천%오효리
儿童%白血病,急性%血清%25羟维生素D3
兒童%白血病,急性%血清%25羥維生素D3
인동%백혈병,급성%혈청%25간유생소D3
Leukemia,Acute%Children%Serum%25-dihydroxyvitaminD3
目的：通过检测儿童急性白血病（AL）血清25羟维生素D3的水平，并探讨其临床意义。方法用双抗体夹心酶联免疫吸附试验（ELISA）方法分别测定60例急性白血病患儿，其中30例急性淋巴细胞白血病（ALL）患儿和30例急性髓细胞白血病（AML）患儿在初诊未治前、缓解1个月后、缓解6个月后和对照组30例健康儿童血清25羟维生素D3的水平，并且对其进行比较。结果血清25羟维生素D3的水平：AL初诊未治组（30.95±6.32）nmol／L，AL缓解1个月组（51.32±14.62） nmol／L，AL缓解6个月组（40.13±9.92）nmol／L；ALL初诊未治组（30.51±13.81）nmol／L，ALL缓解1个月组（61.11±18.93）nmol／L，ALL缓解6个月组（44.43±12.60）nmol／L；AML初诊未治组（31.44±7.13）nmol／L，AML缓解1个月组（41.24±10.29）nmol／L，AML缓解6个月组（36.73±9.73）nmol／L；正常对照组（58.71±8.97）nmol／L。方差分析结果：AL、ALL和AML初诊未治疗组的血清25羟维生素D3的水平均明显低于正常对照组（P＜0.05）。AL （初诊未治组、缓解1个月组、缓解6月组）和ALL（初诊未治组、缓解1个月组、缓解6个月组）各组间血清25羟维生素D3的水平差异有显著性（P＜0.05），AL缓解1个月组和ALL缓解1个月组血清25羟维生素D3的水平与正常对照组差异无显著性；AL和ALL缓解6个月组血清25羟维生素D3的水平低于正常对照组（P＜0.05）。AML三组的血清25羟维生素D3的水平均低于正常对照组（P＜0.05）；ALL与AML初诊未治组血清25羟维生素D3的水平无显著性差异；AL、ALL和AML在化疗过程中血清25羟维生素D3的水平都是先上升，之后又有所下降或者停止上升的趋势。结论动态监测血清25羟维生素D3的水平在儿童急性白血病不同的治疗阶段的变化能够作为判断病情的发展以及评估治疗后效果的一项指标。
目的：通過檢測兒童急性白血病（AL）血清25羥維生素D3的水平，併探討其臨床意義。方法用雙抗體夾心酶聯免疫吸附試驗（ELISA）方法分彆測定60例急性白血病患兒，其中30例急性淋巴細胞白血病（ALL）患兒和30例急性髓細胞白血病（AML）患兒在初診未治前、緩解1箇月後、緩解6箇月後和對照組30例健康兒童血清25羥維生素D3的水平，併且對其進行比較。結果血清25羥維生素D3的水平：AL初診未治組（30.95±6.32）nmol／L，AL緩解1箇月組（51.32±14.62） nmol／L，AL緩解6箇月組（40.13±9.92）nmol／L；ALL初診未治組（30.51±13.81）nmol／L，ALL緩解1箇月組（61.11±18.93）nmol／L，ALL緩解6箇月組（44.43±12.60）nmol／L；AML初診未治組（31.44±7.13）nmol／L，AML緩解1箇月組（41.24±10.29）nmol／L，AML緩解6箇月組（36.73±9.73）nmol／L；正常對照組（58.71±8.97）nmol／L。方差分析結果：AL、ALL和AML初診未治療組的血清25羥維生素D3的水平均明顯低于正常對照組（P＜0.05）。AL （初診未治組、緩解1箇月組、緩解6月組）和ALL（初診未治組、緩解1箇月組、緩解6箇月組）各組間血清25羥維生素D3的水平差異有顯著性（P＜0.05），AL緩解1箇月組和ALL緩解1箇月組血清25羥維生素D3的水平與正常對照組差異無顯著性；AL和ALL緩解6箇月組血清25羥維生素D3的水平低于正常對照組（P＜0.05）。AML三組的血清25羥維生素D3的水平均低于正常對照組（P＜0.05）；ALL與AML初診未治組血清25羥維生素D3的水平無顯著性差異；AL、ALL和AML在化療過程中血清25羥維生素D3的水平都是先上升，之後又有所下降或者停止上升的趨勢。結論動態鑑測血清25羥維生素D3的水平在兒童急性白血病不同的治療階段的變化能夠作為判斷病情的髮展以及評估治療後效果的一項指標。
목적：통과검측인동급성백혈병（AL）혈청25간유생소D3적수평，병탐토기림상의의。방법용쌍항체협심매련면역흡부시험（ELISA）방법분별측정60례급성백혈병환인，기중30례급성림파세포백혈병（ALL）환인화30례급성수세포백혈병（AML）환인재초진미치전、완해1개월후、완해6개월후화대조조30례건강인동혈청25간유생소D3적수평，병차대기진행비교。결과혈청25간유생소D3적수평：AL초진미치조（30.95±6.32）nmol／L，AL완해1개월조（51.32±14.62） nmol／L，AL완해6개월조（40.13±9.92）nmol／L；ALL초진미치조（30.51±13.81）nmol／L，ALL완해1개월조（61.11±18.93）nmol／L，ALL완해6개월조（44.43±12.60）nmol／L；AML초진미치조（31.44±7.13）nmol／L，AML완해1개월조（41.24±10.29）nmol／L，AML완해6개월조（36.73±9.73）nmol／L；정상대조조（58.71±8.97）nmol／L。방차분석결과：AL、ALL화AML초진미치료조적혈청25간유생소D3적수평균명현저우정상대조조（P＜0.05）。AL （초진미치조、완해1개월조、완해6월조）화ALL（초진미치조、완해1개월조、완해6개월조）각조간혈청25간유생소D3적수평차이유현저성（P＜0.05），AL완해1개월조화ALL완해1개월조혈청25간유생소D3적수평여정상대조조차이무현저성；AL화ALL완해6개월조혈청25간유생소D3적수평저우정상대조조（P＜0.05）。AML삼조적혈청25간유생소D3적수평균저우정상대조조（P＜0.05）；ALL여AML초진미치조혈청25간유생소D3적수평무현저성차이；AL、ALL화AML재화료과정중혈청25간유생소D3적수평도시선상승，지후우유소하강혹자정지상승적추세。결론동태감측혈청25간유생소D3적수평재인동급성백혈병불동적치료계단적변화능구작위판단병정적발전이급평고치료후효과적일항지표。
Objective Todetectionthelevelofserum25-dihydroxyvitaminD3andtoexploreits clinicalsignificanceinchildhoodacuteleukemia.Methods Matchedsamplesofinitialtreatment(IT), remission one month(R-1 ),and remission six months(R-6)from 60 children with acute leukemia,among them 30 children with acute lymphoblastic leukemia (ALL)and 30 children with acute myeloid leukemia (AML),as well as 30 samples from healthy children (control)were collected.Double antibody sandwich enzyme-linked immunosorbent assay technology (ELISA ) was used to detect the serum level of serum 25-dihydroxyvitaminD3.Results Serum25-dihydroxyvitaminD3levels:tthelevelwas(30.95±6.32) nmol/L in untreated group(AL),the level was(51 .32 ±1 4.62)nmol/L in remission one month group (AL),the level was (40.1 3 ±9.92)nmol/L in remission six month group(AL),the level was (30.51 ± 1 3.81 )nmol/L in untreated group(ALL),the level was(61 .1 2 ±1 8.93)nmol /L in remission one month group(ALL),the level was (44.43 ±1 2.60)nmol/L in remission six month group(ALL),the level was (31 .44 ±7.1 3)nmol /L in untreated group(AML),the level was(41 .24 ±1 0.29)nmol /L in remission one month group(AML),the level was (36.73 ±9.73)nmol/L in remission six month group(AML),the level was (58.71 ±8.97)nmol/L in normal control group.The differences between untreated groups(AL、ALL)and normal control group had statistical significance (P<0.05 );and the level had not statistical significance between remission one month groups(AL、ALL)and normal control group (P<0.05 );the differences between the three groups of AML and normal control group had statistical significance (P<0.05 ).The serum level of 25-dihydroxy vitamin D3 in IT samples is significantly lower than that in control samples.The differences between untreated groups (ALL、AML)had not statistical significance.Acute leukemia,acute lymphoblastic leukemia and acute myelogenous leukemia during chemotherapy,the levels ofserum25-dihydroxyvitaminD3wentupfirst,thendecreasedorstoppedrising.Conclusions Thelevel of serum 25-dihydroxy vitamin D3 could become a kind of detection index of acute leukemia.In childhood acute leukemia in different stages of treatment,dynamic monitoring the levels of serum 25-dihydroxy vitamin D3 were contributed to judge development of disease and assess treatment effect.
